TRADERPUNKAI-generated research. Not investment advice.TraderPunk is operated by Clickable Company Limited.
PerformanceTermsPrivacyDisclaimerSupport© 2026
Skip to content
TRADERPUNK
StocksPerformancePricingSample report
NYSE · Health Care · Healthcare Plans

UNH

UnitedHealth Group Incorporated

Sells health insurance plans and operates Optum, a division providing pharmacy-benefit management and care services.

$401.73+0.67%
Close · 2026-08-14
Current callSubscribers2026-08-14
$300$350$400
NovFebMayAug
Market context
$254.52
$461.6252-week range, last close at 71% of the range
1W
-1.31%
1M
-4.01%
3M
+2.58%
6M
+38.87%
YTD
+23.34%
1Y
+51.94%
Avg vol 20d
4.4M
RVOL
0.79
HOLD band
Fundamentalsas of 2026-08-14
Mkt cap
$360.59B
P/E
25.8
Fwd P/E
17.9
EPS
$15.56
Div yield
2.31%
Beta
0.63
Employees
390K
Next earnings
2026-10-27
Rating & verdict historyoldest → newest
  1. ✓
  2. ✓
  3. ✗
  4. ✓
  5. ✗
  6. ✗
  7. ✗
DateCallOutcomeReturnTakeaway
2026-08-14Subscribers——Subscribe to read
2026-08-13Subscribers——Subscribe to read
2026-08-12Subscribers——Subscribe to read
2026-08-11Subscribers——Subscribe to read
2026-08-10Subscribers
±1.59%

    • 42.9% correct-0.43% avg moveBUY 0/0 · HOLD 2/4 · SELL 1/3

    —
    —
    Subscribe to read
    2026-08-07SELL✗+0.41%Trim 30–40% of UNH into the $413–$420 resistance zone, reduce target weight to 1.5–2.0% of equity portfolio, retain hedged residual as core defensive compounder. Underweight rating enforced by prior lesson pattern where passive Hold destroyed alpha twice in the last five sessions; mandatory $400/$365 put spread hedge (60–90 DTE, 25–33% of residual) required to neutralize mid-October Q3 2026 binary catalyst. Stop on residual at $397 close; hard exit below $385 on volume. Trim pacing calibrated to August 13 CPI print. Price target $400 over 3–6 months with hard reassessment at Q3 2026 print.
    2026-08-06SELL✗+0.77%Trim 30–40% of UNH exposure at current levels as technical breakdown is confirmed below both the 10 EMA and 50 SMA with a textbook lower-high/lower-low sequence, while buybacks have been paused since H2 2025—suggesting even management doesn't view the stock as undervalued at $414. Retain a smaller core position with mandatory $400/$365 put spread hedge (60–90 DTE, 25–33% of residual) and re-enter either on recovery above $414.86 with MACD improvement or aggressively on capitulation flush to $385–$395.
    2026-08-05HOLD✗-2.13%UNH remains Hold with $450 target and 3-6 month horizon, with three mechanical refinements distinguishing this from prior failed Holds: tightened stop at $395–$400 (vs. trader's $342), pre-committed trim triggers at $400 and $390 volume thresholds, and optional $400/$365 put spread hedge for Q2 2026 earnings as the binary catalyst. The aggressive analyst's bull case is undermined by a factual error—Q1 2026 net income was essentially flat at $6.28B versus Q1 2025's $6.29B, not up 25% YoY—while the conservative analyst's $342 stop is too loose for a name trading 18% above its rising 200 SMA with golden cross confirmed.
    2026-08-04HOLD✓+1.28%Maintain UNH with mandatory $400/$365 put spread hedge (25-33% of position, 60-90 DTE) to neutralize binary October Q3 earnings risk, which directly addresses the lesson that a passive Hold destroyed alpha last time. Pre-committed trim triggers at $380 (25-50% reduction) and $344 (full exit), with a mid-September time-box requiring 15-25% reduction if no confirmed close above $410.64 with volume and MACD bullish cross.
    2026-08-03HOLD✗-1.88%Maintain the core UNH position with no fresh capital deployment ahead of the Q2 2026 binary catalyst, trimming 15-25% on rallies into the $430-450 resistance zone while establishing $400 as the stop-loss level. Add only on confirmed breakout above $436 with volume exceeding 5M shares or on a flush to $390-400 with capitulation volume, as the six failed $436 tests reflect unresolved technical distribution that warrants patience over aggressive positioning.
    2026-07-31HOLD✓+0.23%Maintain neutral Hold on UNH at $414.40 as both aggressive (strong Q1 FCF of $8.15B, debt reduction, Vulcan accumulation) and conservative (compressed margins, goodwill risk, Part D sunset) cases present valid evidence without decisive resolution. Set $425 price target (2.7% above spot) and $396 stop-loss, with Q2 2026 earnings as the binary catalyst: EPS above $6.50 and FY26 guide above $22 upgrades to Overweight, while a miss or guide cut downgrades to Underweight.
    2026-07-30SELL✓-1.68%Trim UNH 20-30% to materially below benchmark weight given confirmed technical distribution (failed double-top at $436, price below 10 EMA/Bollinger midline/VWAP), 18.8x forward P/E premium to healthcare's 14-16x range, and locked-in Part D repricing headwind hitting 2027 P&L. Maintain residual position as the long-term uptrend (50 SMA rising from $284 to $408, golden cross confirmed), Q2 margin recovery, and Vulcan Value Partners accumulation support the franchise thesis; do not initiate new longs at $421.